Focused On-demand Library for MAP kinase-activated protein kinase 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q16644

UPID:

MAPK3_HUMAN

Alternative names:

Chromosome 3p kinase

Alternative UPACC:

Q16644; B5BU67

Background:

MAP kinase-activated protein kinase 3, also known as Chromosome 3p kinase, plays a pivotal role in stress response, cytokine production, and cell migration. It is activated by MAP kinase p38-alpha/MAPK14, leading to the phosphorylation of various substrates including HSP27/HSPB1, KRT18, and TTP/ZFP36. Its involvement in chromatin remodeling and transcriptional regulation underscores its importance in cellular processes.

Therapeutic significance:

The association of MAP kinase-activated protein kinase 3 with Macular dystrophy, patterned, 3, highlights its potential as a therapeutic target. Understanding the role of this protein could open doors to potential therapeutic strategies for treating retinal diseases.